Muenst S - Search Results

1

Diagnostic and prognostic utility of PD-1 in B cell lymphomas.

Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A. Muenst S, et al. Dis Markers. 2010;29(1):47-53. doi: 10.3233/DMA-2010-0725. Dis Markers. 2010. PMID: 20826917 Free PMC article.

2

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.

Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Muenst S, et al. Hum Pathol. 2009 Dec;40(12):1715-22. doi: 10.1016/j.humpath.2009.03.025. Epub 2009 Aug 19. Hum Pathol. 2009. PMID: 19695683

3

Distribution of PD-1+ lymphocytes in reactive lymphadenopathies.

Muenst S, Dirnhofer S, Tzankov A. Muenst S, et al. Pathobiology. 2010;77(1):24-7. doi: 10.1159/000272951. Epub 2010 Feb 25. Pathobiology. 2010. PMID: 20185964 Free article.

4

[Embolization of hydrophilic guide wire coating].

Muenst S, Willi N, Cathomas G, Jeger RV, Soysal SD, Glatz K. Muenst S, et al. Pathologe. 2012 Jul;33(4):345-7. doi: 10.1007/s00292-012-1588-6. Pathologe. 2012. PMID: 22555363 German.

5

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. Muenst S, et al. Breast Cancer Res Treat. 2013 Jun;139(3):667-76. doi: 10.1007/s10549-013-2581-3. Epub 2013 Jun 12. Breast Cancer Res Treat. 2013. PMID: 23756627 Free PMC article.

6

Nuclear expression of snail is an independent negative prognostic factor in human breast cancer.

Muenst S, Däster S, Obermann EC, Droeser RA, Weber WP, von Holzen U, Gao F, Viehl C, Oertli D, Soysal SD. Muenst S, et al. Dis Markers. 2013;35(5):337-44. doi: 10.1155/2013/902042. Epub 2013 Sep 22. Dis Markers. 2013. PMID: 24191127 Free PMC article.

7

Author's response to "Letter to the editor: unvalidated antibodies and misleading results".

Muenst S, Tzankov A, Gillanders WE, Soysal SD. Muenst S, et al. Breast Cancer Res Treat. 2014 Sep;147(2):459-62. doi: 10.1007/s10549-014-3064-x. Breast Cancer Res Treat. 2014. PMID: 25082517 No abstract available.

8

The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.

Muenst S, Soysal SD, Tzankov A, Hoeller S. Muenst S, et al. Expert Opin Ther Targets. 2015 Feb;19(2):201-11. doi: 10.1517/14728222.2014.980235. Epub 2014 Dec 10. Expert Opin Ther Targets. 2015. PMID: 25491730 Review.

9

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S. Tzankov A, et al. Among authors: muenst s. J Hematol Oncol. 2015 Jun 14;8:70. doi: 10.1186/s13045-015-0168-7. J Hematol Oncol. 2015. PMID: 26071053 Free PMC article.

10

Role of the Tumor Microenvironment in Breast Cancer.

Soysal SD, Tzankov A, Muenst SE. Soysal SD, et al. Pathobiology. 2015 Sep;82(3-4):142-52. doi: 10.1159/000430499. Epub 2015 Aug 31. Pathobiology. 2015. PMID: 26330355 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page